Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 203

1.

High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden.

Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC.

Hematology. 2008 Apr;13(2):71-6. doi: 10.1179/102453308X315960.

PMID:
18616871
2.

The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.

Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC.

Eur J Haematol. 2007 Dec;79(6):508-15. Epub 2007 Oct 23.

PMID:
17961178
3.

Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients.

Patriarca A, Pompetti F, Malizia R, Iuliani O, Di Marzio I, Spadano A, Dragani A.

Blood Transfus. 2010 Jan;8(1):21-7. doi: 10.2450/2009.0004-09.

4.

Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients.

Besses C, Alvarez-Larrán A, Martínez-Avilés L, Mojal S, Longarón R, Salar A, Florensa L, Serrano S, Bellosillo B.

Br J Haematol. 2011 Feb;152(4):413-9. doi: 10.1111/j.1365-2141.2010.08467.x. Epub 2011 Jan 10.

PMID:
21219298
5.

Comparison of JAK2V617F mutation assessment employing different molecular diagnostic techniques.

Veneri D, Capuzzo E, de Matteis G, Franchini M, Baritono E, Benati M, Solero GP, Ambrosetti A, Quaresmini G, Pizzolo G.

Blood Transfus. 2009 Jul;7(3):204-9. doi: 10.2450/2009.0070-08.

6.

The role of serum erythropoietin level and JAK2 V617F allele burden in the diagnosis of polycythaemia vera.

Ancochea A, Alvarez-Larrán A, Morales-Indiano C, García-Pallarols F, Martínez-Avilés L, Angona A, Senín A, Bellosillo B, Besses C.

Br J Haematol. 2014 Nov;167(3):411-7. doi: 10.1111/bjh.13047. Epub 2014 Jul 18.

PMID:
25040297
7.

Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.

Ha JS, Kim YK, Jung SI, Jung HR, Chung IS.

Ann Lab Med. 2012 Nov;32(6):385-91. doi: 10.3343/alm.2012.32.6.385. Epub 2012 Oct 17.

8.

Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.

Hexner E, Roboz G, Hoffman R, Luger S, Mascarenhas J, Carroll M, Clementi R, Bensen-Kennedy D, Moliterno A.

Br J Haematol. 2014 Jan;164(1):83-93. doi: 10.1111/bjh.12607. Epub 2013 Oct 28.

PMID:
24903629
9.

Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.

Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foà R, Larocca LM.

J Clin Oncol. 2007 Mar 20;25(9):1048-53.

PMID:
17369568
10.

JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera.

Carobbio A, Finazzi G, Antonioli E, Guglielmelli P, Vannucchi AM, Dellacasa CM, Salmoiraghi S, Delaini F, Rambaldi A, Barbui T.

Exp Hematol. 2009 Sep;37(9):1016-21. doi: 10.1016/j.exphem.2009.06.006. Epub 2009 Jun 24.

11.

[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].

Iványi JL, Marton E, Plander M.

Orv Hetil. 2011 Nov 6;152(45):1795-803. doi: 10.1556/OH.2011.29226. Hungarian.

PMID:
22011365
12.

Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.

Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC, Colomer D, Villamor N, Bellosillo B, Cervantes F.

Am J Hematol. 2009 Feb;84(2):102-8. doi: 10.1002/ajh.21338.

13.

The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.

Borowczyk M, Wojtaszewska M, Lewandowski K, Gil L, Lewandowska M, Lehmann-Kopydłowska A, Kroll-Balcerzak R, Balcerzak A, Iwoła M, Michalak M, Komarnicki M.

Thromb Res. 2015 Feb;135(2):272-80. doi: 10.1016/j.thromres.2014.11.006. Epub 2014 Nov 15.

PMID:
25559461
14.

Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia.

Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, Longo G, Ponziani V, Tozzi L, Pieri L, Santini V, Bosi A, Vannucchi AM; Myeloproliferative Disorders Research Consortium (MPD-RC).

Haematologica. 2008 Jan;93(1):41-8. doi: 10.3324/haematol.11653.

15.

Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation.

De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Micò C, Tieghi A, Cacciola RR, Santoro C, Vianelli N, Guglielmelli P, Pieri L, Scognamiglio F, Cacciola E, Rodeghiero F, Pogliani EM, Finazzi G, Gugliotta L, Leone G, Barbui T; GIMEMA Chronic Myeloproliferative Neoplasms Working Party.

Ann Hematol. 2010 Feb;89(2):141-6. doi: 10.1007/s00277-009-0788-5. Epub 2009 Jul 7.

PMID:
19582452
16.

Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders.

Basquiera AL, Soria NW, Ryser R, Salguero M, Moiraghi B, Sackmann F, Sturich AG, Borello A, Berretta A, Bonafé M, Barral JM, Palazzo ED, García JJ.

Hematology. 2009 Dec;14(6):323-30. doi: 10.1179/102453309X12473408860226.

PMID:
19941738
17.

Proteomic study of the impact of the JAK2-V617F mutation on the phenotype of essential thrombocythemia.

Mossuz P, Arlotto M, Hermouet S, Bouamrani A, Lippert E, Girodon F, Dobo I, Vincent P, Cahn JY, Berger F.

Exp Hematol. 2008 Dec;36(12):1642-7. doi: 10.1016/j.exphem.2008.07.013. Epub 2008 Oct 5.

PMID:
18838204
18.

[Clinical significance of the quantification of JAK2V617F allele burden in classical Ph-negative myeloproliferative neoplasms].

Kerguelén Fuentes AE, Hernández-Maraver D, Lombardia L, Canales Albendea MA, Rodriguez de la Rúa A.

Med Clin (Barc). 2012 Oct 13;139(9):373-8. doi: 10.1016/j.medcli.2012.03.032. Epub 2012 Jun 27. Spanish.

PMID:
22743278
19.

Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).

Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.

Pathol Biol (Paris). 2007 Mar;55(2):92-104. Epub 2006 Aug 21. Review.

PMID:
16919893
20.

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, Them NC, Berg T, Elena C, Casetti IC, Milanesi C, Sant'antonio E, Bellini M, Fugazza E, Renna MC, Boveri E, Astori C, Pascutto C, Kralovics R, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators.

Blood. 2014 Mar 6;123(10):1544-51. doi: 10.1182/blood-2013-11-539098. Epub 2013 Dec 23.

Supplemental Content

Support Center